Stockscreener 앱 받기
5.34
0.09%
0.00
전일 마감가:
$5.34
열려 있는:
$5.32
하루 거래량:
219.47K
Relative Volume:
0.45
시가총액:
$1.20B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
9.7374
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-0.65%
1개월 성능:
-1.93%
6개월 성능:
+50.14%
1년 성능:
+93.66%
1일 변동 폭
$5.32
$5.36
1주일 범위
$5.32
$5.38
52주 변동 폭
$2.37
$5.72
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.34 | 1.20B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.50 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.98 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.29 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
BioNTech (NASDAQ: BNTX) reports €1,518.9M revenue, net loss €28.7M; raises FY outlook - Stock Titan
Relative strength of CureVac N.V. in sector analysisMarket Movers & AI Enhanced Execution Alerts - newser.com
Understanding CureVac N.V.’s price movementPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Smart tools for monitoring CureVac N.V.’s price actionBuy Signal & Safe Capital Preservation Plans - newser.com
Historical volatility pattern of CureVac N.V. visualizedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Using data tools to time your CureVac N.V. exitJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
How interest rate cuts could boost CureVac N.V. stockMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
Will CureVac N.V. stock benefit from green energy trendsMarket Growth Report & Real-Time Volume Analysis - newser.com
Why CureVac N.V. stock is a value investor pickWeekly Trend Report & Verified Technical Trade Signals - newser.com
Can CureVac N.V. stock resist market sell offsRisk Management & Technical Confirmation Alerts - newser.com
How currency fluctuations impact CureVac N.V. stock2025 AllTime Highs & Free Reliable Trade Execution Plans - newser.com
Is CureVac N.V. stock positioned for digital transformation2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
CureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer Treatment - MSN
CureVac Announces Extraordinary Meeting for Merger with BioNTech - MSN
CureVac N.V. (NASDAQ:CVAC) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Is CureVac N.V. stock supported by strong fundamentalsOptions Play & Safe Capital Growth Plans - Fundação Cultural do Pará
Analyzing net buyer seller activity in CureVac N.V.Options Play & Precise Trade Entry Recommendations - newser.com
Is CureVac N.V. stock ready for breakoutMarket Activity Report & Risk Controlled Swing Trade Alerts - fcp.pa.gov.br
CureVac schedules extraordinary shareholder meeting for November 25 By Investing.com - Investing.com South Africa
CureVac schedules extraordinary shareholder meeting for November 25 - Investing.com
CureVac schedules extraordinary meeting; releases proxy and merger docs - Stock Titan
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
0.84%
자본화:
|
볼륨(24시간):